Our Research
Mission Statement
Men’s Health Clinic Manitoba was created to be a one-stop shop for comprehensive Men’s Health Care. We strive to offer the latest and most evidence-based technology to our patients. We also provide recruitment for robust clinical trials and prospective studies to push the boundaries for Men’s Health research globally.
Fellowship
We offer a comprehensive 12-month Fellowship in Male Infertility, Sexual Medicine & Cancer Survivorship. Men’s Health Clinic Manitoba is a high volume facility and has its own procedural suites and an operating theatre with its own operating microscope to facilitate the vast majority of procedures on-site. Apart from Male Infertility & Sexual Medicine, the Fellow will get exposure to minimally invasive surgical therapies for Benign Prostatic Hyperplasia. Further, the Fellow will be exposed to office-based surgical procedures for the majority of scrotal and penile surgery (hydrocelectomy, spermatocelectomy, penile plication, etc…)
For interested applicants, please contact info@mhclinic.ca.
Current Projects
Objectives
Currently, there is a large interest in minimally invasive treatment options to improve symptoms from an enlarged prostate. The Spring device gently props open the urethral opening to restore flow. Prior studies have demonstrated safety and good short-term outcomes.
Details
Men wishing to participate will be randomly assigned (2:1) to either the treatment group (Spring device) or the placebo group. For those in the placebo arm, they can choose to receive the device after 3 months. Men will be followed up for up to 5 years.
Participants
Men with symptomatic BPH, prostate volume between 20 and 80 gm and prostatic urethral length between 32 and 55 mm (as determined by TRUS) who are willing and able to comply with the requirements of the study.
Enrolment
If you are interested in learning more about the trial and want to see if you are eligible, please contact: info@mhclinic.ca or call the office: 204-817-0153
Objectives
Currently, there is no standardized treatment for Chronic Scrotal Content Pain. Lidocaine injections are often used but unfortunately have a relatively short-lasting effect. This study aims to look at ST-01 (Sustained-Release Lidocaine Polymer Solution for Injection) as a vehicle to extend the pain mediating effects of lidocaine. Previous studies have shown safety and good short-term outcomes.
Details
Men selected for the study will be randomized into either the ST-01 treatment group or the lidocaine only control group. Participants in the lidocaine only control group will have the option to switch over into the ST-01 treatment group once they have had 2 lidocaine only injections, 28 days apart. Subjects will be followed for 16 weeks following the first treatment.
Participants
Men who are > 19 with unilateral or bilateral scrotal pain for >3 months who are willing and able to comply with the study requirements.
Enrolment
If you are interested in learning more about the trial and would like to see if you are eligible, please contact: info@mhclinic.com or call the office: 204-817-0153
Objectives
BPH is enlarged prostate tissue that can partially and completely block normal urine flow. Common treatments include medical or surgical interventions like the Optilume BPH Catheter. This study will continue to evaluate the safety and effectiveness of the catheter system in the normal population. Previous studies have shown safety and good short-term outcomes.
Details
Men selected for the study will have the Optilume BPH Catheter system inserted then will be followed for up to one year post procedure.
Participants
Men with symptomatic BPH, a prostate volume between 20 and 80 gm and prostatic urethral length between 32 and 55 mm (as determined by TRUS) who are willing and able to comply with the requirements of the study.
Enrolment
If you are interested in learning more about the trial and would like to see if you are eligible, please contact: info@mhclinic.com or call the office: 204-817-0153
Objectives
For men diagnosed with advanced or metastatic prostate cancer, Androgen Deprivation Therapy (ADT) Intensification has been established as the standard of care. However, little is known about the real-world use of this course of treatment. This study will look at the use of ADT Intensification by Canadian Community Urologists in the treatment of prostate cancer.
Details
This study requires the consent of the patient that will allow us to access and evaluate current medical records on an annual basis for 3 years. No additional clinic visits will be required.
Participants
Eligible candidates for this study will be those with a confirmed diagnosis of prostate cancer who have either started Zoladex in the last 3 months or will be starting Zoladex in the next 3 months.
Enrolment
If you are interested in learning more about the trial and would like to see if you are eligible, please contact: info@mhclinic.com or call the office: 204-817-0153.
Donate.
A charitable receipt will be provided for your generous gift. (Chartable registration #11895 5012 RR0001)
Having published over 100-peer reviewed manuscripts, conference abstracts and book chapters and having numerous grants, Drs. Patel and Nayak are actively involved in research. Dr. Patel also serves as Director of Urologic Research for the Section of Urology at the University of Manitoba. A Research Fund has been developed through the Health Sciences Centre Foundation to support the research being conducted at MHC.
For Donations to Men’s Health Research Fund please fill out the form and we will get back to you with next steps:
